ABBV 444
Alternative Names: ABBV-444Latest Information Update: 02 Jan 2024
At a glance
- Originator AbbVie
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Dry eyes
Most Recent Events
- 06 Oct 2023 AbbVie completes a phase III trial in Dry eyes in USA (Ophthalmic) (NCT05878067)
- 26 May 2023 Phase-III clinical trials in Dry eyes in USA (Ophthalmic) (NCT05878067)